Long-read Genome Sequencing for the Molecular Diagnosis of Dystonia

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorUniversity Hospital, Strasbourg, France

About this trial

Dystonia is a motor disorder caused by involuntary, intermittent, or sustained muscle contractions, leading to abnormal movements or postures. It can affect any body region and often results in significant functional disability and healthcare burden. Although its familial nature was recognized early on, the advent of high-throughput DNA sequencing has dramatically increased the identification of dystonia-associated genes. Dystonia now encompasses all modes of inheritance-autosomal dominant (e.g., TOR1A, KMT2B), autosomal recessive, X-linked, and mitochondrial-and over 100 genes have been implicated. Many forms involve structural variants (SVs) or copy number variations (CNVs), which are challenging to detect using standard short-read sequencing (srWGS).

Molecular diagnosis is essential, ending the diagnostic odyssey and enabling genetic counseling, prognosis, reproductive planning, and-in some cases-targeted therapies. For instance, GNAO1-related dystonia may respond to deep brain stimulation, while dopa-responsive dystonia benefits from levodopa.

Despite advances, srWGS has key limitations, especially for detecting repeat expansions, SVs, and phasing alleles. This likely explains the low diagnostic yield in dystonia compared to other neurological disorders, with over 70% of cases remaining unsolved.

Long-read sequencing (lrWGS), such as Oxford Nanopore technology, overcomes many of these challenges by reading native DNA fragments thousands of bases long. It enables comprehensive detection of SNVs, indels, SVs, CNVs, methylation changes, and repeat expansions-including known and newly discovered pathogenic expansions (e.g., in NOTCH2NLC). It also allows phasing without parental samples, which is crucial in recessive cases.

The investigators propose that lrWGS could significantly increase the diagnostic yield in dystonia, improving patient care, enabling appropriate genetic counseling, and paving the way for personalized treatment strategies.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Index case affected by familial dystonia (≥1 first-degree relative affected) and/or sporadic early-onset dystonia (symptom onset before age 50), meeting the criteria of the PFMG-2025 program.

Index case who has undergone short-read genome sequencing, which did not lead to a molecular diagnosis.

Ability to understand and sign informed consent by the index case and/or their parents or legal guardians for patients under 18 years of age.

Availability of a blood sample from the index case and at least two relatives, either affected or unaffected.

Disqualifiers

Index case or relatives who are not affiliated with or not beneficiaries of a social security scheme.

Index case and their parents presenting with a condition that, in the opinion of the investigator, would contraindicate participation in the study.

Suspected non-genetic etiology (e.g., perinatal hypoxic-ischemic injury, kernicterus, history of severe head trauma or central nervous system infection).

Trial design

Design model

Single group

Treatments tested in this trial

  • Long-read whole genome sequencing

    Diagnostic test

    Pseudonymized blood samples will undergo high-molecular-weight DNA extraction, followed by long-read whole-genome sequencing (lrWGS) using Oxford Nanopore technology. Index cases will be sequenced at high depth (\>30X), while relatives will be multiplexed (\>15X). Sequencing data will be analyzed through a dedicated bioinformatics pipeline to detect SNVs, indels, structural variants, and repeat expansions. Results will be interpreted by expert teams and discussed in monthly clinical-genetic meetings. Variants of interest will be validated by appropriate molecular techniques, and family segregation will be assessed when relevant.

Treatment groups

150 Participants
are divided into 1 treatment group
Group A: Dystonia patients without molecular diagnosisExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Long-read genome sequencing diagnostic rate

Proportion (expressed as a percentage) of families in which a causal genetic variant (classified as class 4 or 5 according to the American College of Medical Genetics and Genomics) explaining the patients' symptoms was identified through long-read genome sequencing, after no diagnosis had been reached using prior short-read genome analysis.

Time frame
18 months

Secondary outcomes

1

Technical issues rate

Proportion (expressed as a percentage) of families for whom technical difficulties were encountered during long-read genome sequencing and analysis, the proportion for whom solutions were identified, and the proportion for whom it was not possible to obtain a result

Time frame
18 months
2

Proportion of activable disorders

Proportion (percentage) of families for whom the molecular diagnosis led to a change in clinical management, including therapeutic modification; genetic counseling, prenatal or preimplantation diagnosis for the index case or relatives; detection of a disease-specific complication in the index case or relatives.

Time frame
24 months
3

New molecular causes of dystonia

Proportion (percentage) of families whose molecular diagnosis revealed a previously unreported genetic cause of dystonia.

Time frame
18 months
4

Resolution following reanalysis of short-read whole genome sequencing data

Proportion (percentage) of families in which a causal genetic variant was identified using dedicated bioinformatic tools during retrospective reanalysis of the short-read genome.

Time frame
18 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.